Baylor inks anti-cancer vax development pact

Japan-based SBI Biotech and Baylor Research Institute have inked a licensing deal and development agreement to develop anti-cancer vaccines for Asian markets, which could possibly include Japan, Taiwan and Korea.

The licensing agreement allows SBI to conduct clinical trials on early-stage cancer patients using Baylor's "dentritic cell immunotherapy"--a treatment designed to work in conjunction with others, such as radiation and chemotherapy. Over the past five years, the Dallas-based institute's clinical trials have only included about 100 cancer patients, all of whom have had late-stage cancer and declining immune systems.

Under the terms of the agreement, SBI will pay Baylor about $3 million in acceleration fees and another $3 million in SBI stock, with potential milestone and royalty fees that could reach a half-million.

- check out the Dallas Business Journal for more

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.